A sales rep for Grifols is accusing the Spanish drug maker of illegally marketing an expensive orphan drug and defrauding US health care programs in a whistleblower lawsuit that was unsealed in federal court.
In her complaint, Heather Murray contends that Grifols management deliberately attempted to widen the otherwise narrow market for a drug called Thrombate III, which is used to treat hereditary antithrombin deficiency, a condition in which people are at higher risk of developing blood clots. The ailment occurs in about 1 in every 2,000 to 3,000 individuals, according to government estimates.
About the Author Reprints
To heck with Murray. Congenital ATIII Deficiency has an 85% mortality rate in childhood. I’d prescribe it for my child in a New York nanosecond.
Recently I’ve been unable to read pharmalot articles when I go to the site and although I’ve signed up for the newsletter I haven’t yet received anything. How do I access this informational report? Thanks